1. Home
  2. PHIN vs NRIX Comparison

PHIN vs NRIX Comparison

Compare PHIN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PHINIA Inc.

PHIN

PHINIA Inc.

HOLD

Current Price

$57.16

Market Cap

2.3B

Sector

N/A

ML Signal

HOLD

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$25.11

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHIN
NRIX
Founded
2023
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.6B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
PHIN
NRIX
Price
$57.16
$25.11
Analyst Decision
Buy
Buy
Analyst Count
5
14
Target Price
★ $91.60
$34.50
AVG Volume (30 Days)
381.2K
★ 1.7M
Earning Date
10-29-2026
10-12-2026
Dividend Yield
★ 2.07%
N/A
EPS Growth
★ 84.09
N/A
EPS
2.01
★ 3.26
Revenue
N/A
★ $76,987,000.00
Revenue This Year
$4.59
$786.93
Revenue Next Year
$3.61
N/A
P/E Ratio
$28.74
★ $7.51
Revenue Growth
N/A
★ 99.31
52 Week Low
$51.28
$10.15
52 Week High
$86.94
$28.23

Technical Indicators

Market Signals
Indicator
PHIN
NRIX
Relative Strength Index (RSI) 34.39 58.82
Support Level N/A $24.61
Resistance Level $81.54 $28.23
Average True Range (ATR) 1.49 1.11
MACD 0.21 0.31
Stochastic Oscillator 32.38 92.61

Price Performance

Historical Comparison
PHIN
NRIX

About PHIN PHINIA Inc.

Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, it generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: